ea0029p1369 | Pituitary Clinical | ICEECE2012
Auriemma R.
, Grasso L.
, Di Sarno A.
, Perone Y.
, Pivonello R.
, Colao A.
Cabergoline (CAB) and other dopamine agonists are usually discontinued shortly after hyperprolactinemic patients become pregnant. Data on maternal and foetal exposure to CAB and on recurrence of hyperprolactinemia after pregnancy are still limited. The current survey study aimed at elucidating the safety of exposure to CAB during early pregnancy and the recurrence rate of hyperprolactinemia after pregnancy. Thus, 68 pregnancies in a cohort of 59 patients with hyperprolactinemi...